Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Korea Inc.
Age
4–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Participants with approved indication for Fycompa (Perampanel) in Korea as follows:
* Monotherapy (film-coated tablets)
o 4 years and older Partial-onset seizures: therapy for treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy
* 4 years and older Partial-onset seizures: therapy for treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy
* 7 years and older Primary generalized tonic-clonic seizures: therapy for treatment of primary generalized tonic-clonic seizures in participants with idiopathic generalized epilepsy
2. Participants who have written consent for use of personal and medical information for the study purpose
You may not be if
1. Hypersensitivity to the active substance or to any of the excipients of this medicine
2. In case of Fycompa film-coated tablets, Fycompa tablets contains lactose; therefore, participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine. In case of Fycompa oral suspension, Fycompa suspension contains sorbitol; therefore, participants with rare hereditary problems of fructose intolerance should not take this medicine.
3. Other participants judged to be inadequate to participate in the study by doctor
Clareo Health | A Study of Fycompa (Perampanel) in Korean Participants
